| Therapyworks, Pa | |
|
1311 Wakarusa Dr, Suite 1000, Lawrence, KS 66049-4798 | |
| (785) 749-1300 | |
| (785) 749-4746 |
| Full Name | Therapyworks, Pa |
|---|---|
| Type | Facility |
| Speciality | Clinic/center - Physical Therapy |
| Location | 1311 Wakarusa Dr, Lawrence, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497705321 | NPI | - | NPPES |
| 100297720A | Medicaid | KS | |
| 22938015 | Other | KS | BCBS OF KANSAS CITY |
| 370813200 | Other | KS | DEPT OF LABOR |
| 623280 | Other | KS | FIRSTGUARD |
| 22938015 | Other | KS | PHP |
| 014727 | Other | KS | BCBS OF KS |
| 5548578 | Other | KS | AETNA |
| 100077430A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Secondary |
| 261QP2000X | Clinic/center - Physical Therapy | (* (Not Available)) | Primary |
| Provider Name | Jonathan Richard Jones |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1407953722 PECOS PAC ID: 3173512928 Enrollment ID: I20040507000994 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | Mark D Luttrell |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1699936260 PECOS PAC ID: 3870667116 Enrollment ID: I20080804000504 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | Cynthia E Johnson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1821043035 PECOS PAC ID: 9133195712 Enrollment ID: I20081204000294 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | Shweta Kishorkumar Shah |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1598038077 PECOS PAC ID: 5395903330 Enrollment ID: I20150615001737 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | Lauren A Cerier |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164873972 PECOS PAC ID: 4789967084 Enrollment ID: I20170213000335 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | Megan Remmert |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417404195 PECOS PAC ID: 3476836388 Enrollment ID: I20170220000131 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | Jordan S Umscheid |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1306376645 PECOS PAC ID: 8729358858 Enrollment ID: I20170724001775 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | Lindsay Y Munoz |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932693868 PECOS PAC ID: 7618224817 Enrollment ID: I20180719000206 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | Taylor L Grabowski |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760976716 PECOS PAC ID: 1052660362 Enrollment ID: I20180820003731 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | Brandi Lynn Goss |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1235543067 PECOS PAC ID: 5597983742 Enrollment ID: I20200527000779 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | Laura D Olson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1528664521 PECOS PAC ID: 2567874605 Enrollment ID: I20201215001958 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | Catherine Grace Lucas |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1003408675 PECOS PAC ID: 2365857703 Enrollment ID: I20210218000098 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Provider Name | James Quinn |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1275061442 PECOS PAC ID: 4981946290 Enrollment ID: I20210503001707 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Therapyworks, Pa 1311 Wakarusa Dr, Suite 1000, Lawrence, KS 66049-4798 Ph: (785) 749-1300 | Therapyworks, Pa 1311 Wakarusa Dr, Suite 1000, Lawrence, KS 66049-4798 Ph: (785) 749-1300 |
News Archive
Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study from researchers at the University of Wisconsin-Madison.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest.
› Verified 9 days ago